GLOW Blend protocol

Standard

Week 1

10u

1 mg · Daily

Loading. 1 mg GHK-Cu + 0.2 mg BPC-157 + 0.2 mg TB-500 per dose.

Week 2

15u

1.5 mg · Daily

Ramp. 1.5 mg GHK-Cu + 0.3 mg BPC + 0.3 mg TB per dose.

Weeks 3–8

20u

2 mg · Daily

Working dose. 2 mg GHK-Cu + 0.4 mg BPC + 0.4 mg TB per dose.

Off

4 weeks

Mandatory copper-accumulation washout. Do not skip, especially after an Aggressive phase.

Phase	How often	Dose	Units	Notes
Week 1	Daily	1 mg	10u	Loading. 1 mg GHK-Cu + 0.2 mg BPC-157 + 0.2 mg TB-500 per dose.
Week 2	Daily	1.5 mg	15u	Ramp. 1.5 mg GHK-Cu + 0.3 mg BPC + 0.3 mg TB per dose.
Weeks 3–8	Daily	2 mg	20u	Working dose. 2 mg GHK-Cu + 0.4 mg BPC + 0.4 mg TB per dose.
Off	4 weeks	–	–	Mandatory copper-accumulation washout. Do not skip, especially after an Aggressive phase.

Dose is the GHK-Cu component per dose.

Aggressive

30–40u

3–4 mg · Daily (AM + PM split)

Bump here ONLY if 2+ weeks at 2 mg with zero injection-site issues AND a specific high-demand goal. Start at 3 mg (= 0.6 mg each of BPC/TB). Push to 4 mg only if 3 mg is producing visible results and you want to test further, no published benefit above 3 mg/day; cost roughly doubles.

Phase	How often	Dose	Units	Notes
Aggressive	Daily (AM + PM split)	3–4 mg	30–40u	Bump here ONLY if 2+ weeks at 2 mg with zero injection-site issues AND a specific high-demand goal. Start at 3 mg (= 0.6 mg each of BPC/TB). Push to 4 mg only if 3 mg is producing visible results and you want to test further, no published benefit above 3 mg/day; cost roughly doubles.

Cycle & timing

Cycle: 8 weeks on / 4 weeks off, matches GHK-Cu copper-accumulation limits.

Timing: Daily SubQ, anytime; same as the Wolverine base.

Where: SubQ near target tissue. Rotate.

What to expect

Broad tissue repair, skin quality improvement, and anti-inflammatory effects build over the 8-week cycle. 4-week washout follows.

How much to buy

For 8-wk @ 2 mg × 7/wk:

3

× 70mg vials

Men & women

Unisex (GHK-Cu + BPC-157 + TB-500 repair / skin), same protocol for men and women, no cycle effect. Avoid in pregnancy.

Recommended mixes

Vial	Water	Strength
70 mg	5 mL	GHK-Cu 10 mg/mL; BPC-157 2 mg/mL; TB-500 2 mg/mL

70 mg: 1 unit = 0.10 mg

Storage

PowderFreeze-dried: -4°F.
MixedReconstituted: 36–46°F, protected from light, 6 weeks (rate-limited by GHK-Cu component).

Don't use if: Active malignancy (TB-500 promotes angiogenesis; BPC-157 promotes tissue growth) · Wilson's disease, copper dysregulation, copper allergy (GHK-Cu component) · Active bleeding or recent hemorrhagic stroke (TB-500 vascular effects) · Pregnancy, lactation

Stop if you notice

New mass or unexpected tissue growth at any injection site
Skin discoloration, neurological symptoms (copper toxicity from GHK-Cu)
Persistent injection-site reactions beyond 7 days

Side effects

Usually minimal. Injection-site irritation occasionally.

Drug interactions

NSAIDs: don't blunt the blend (a myth); skip during a repair cycle, NSAIDs slow healing themselves. High-dose vitamin C same session: theoretical copper-ascorbate redox interaction with GHK-Cu. Anticoagulants (warfarin, DOACs): caution with TB-500 vascular effects.

Labs

Compound-specific: hsCRP (baseline + end). Serum copper and ceruloplasmin if cycles extend beyond 6 weeks (GHK-Cu accumulation). Out of range? Rising serum copper / ceruloplasmin = copper is accumulating → pause and re-dose lower.

What these labs mean →

Warnings

Combines three compounds with no human RCT data on the blend itself. Quality varies by compounder; request COA listing each component's purity. GHK-Cu: extended continuous use can cause copper accumulation, the 6-week off period is critical. BPC-157: FDA Category 2 in 2023; compounding from bulk substances is restricted. TB-500: no published human efficacy trials; theoretical malignancy risk via angiogenesis. BPC-157 & TB-500 were both RECOMMENDED for the 503A bulks list by PCAC (8–6 each, Jul 2026; advisory, non-binding).

Patient education

Three-peptide blend: any single-component contraindication applies to the whole blend. Cycle discipline matters more than dose: 6 weeks on / 6 weeks off is the canonical pattern. Inject SubQ near target tissue. Rotate sites to reduce GHK-Cu sting.

These apply on top of the universal safety rules.

Pairs well with

CJC-1295 No DAC + Ipamorelin

systemic GH + local repair

CJC-1295 (No DAC) + Ipamorelin

Thymosin Alpha-1

immune support

Thymosin Alpha-1

Epithalon

longevity / collagen complement

Epithalon

Avoid with

NSAIDs during a repair cycle

ibuprofen/Advil/Aleve slow healing on their own; use Tylenol for pain

High-dose vitamin C same session

copper oxidation

Can GLOW Blend + CJC-1295 (No DAC) + Ipamorelin share a syringe?

Can share a syringe. Both are water-based. Combine them if you dose on the same schedule and site.

Changes from the guide

The guide contradicted itself or had a slip here, so this page differs from the PDF:

The guide said 2 × 70 mg vials; the ramp needs about 10.15 mL, just over two 5 mL vials, so 3.

What it does

Three-peptide regenerative blend: GHK-Cu (4,000+ repair genes) + TB-500 (systemic repair) + BPC-157 (healing). Pre-mixed convenience. TB-500 upregulates thymosin β4 for systemic repair. BPC-157 drives local angiogenesis.

Supply math note

70 mg vial covers ~half of an 8-week cycle at 2 mg/day; reconstituted shelf life ~28 days. Aggressive 3–4 mg/day depletes the vial faster but stays inside the discard window.

References

researchdosing peptidedosages PubMed thepeptidereport peptides.id

From the guide, page 37.